Legal Representation
Attorney
TRACY-GENE G. DURKIN
USPTO Deadlines
Application History
43 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Oct 8, 2025 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | Loading... |
| Oct 8, 2025 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Jul 12, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jul 12, 2024 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
| Jul 12, 2024 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
| Jul 12, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jan 18, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jan 16, 2024 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Jan 16, 2024 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Jan 16, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jul 15, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jul 13, 2023 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Jul 13, 2023 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Jul 13, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jan 20, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jan 18, 2023 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Jan 18, 2023 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Jan 18, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jul 19, 2022 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| May 24, 2022 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| May 24, 2022 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| May 4, 2022 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Apr 20, 2022 | EXPT | T | EXPARTE APPEAL TERMINATED | Loading... |
| Apr 20, 2022 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Apr 12, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Apr 12, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Apr 11, 2022 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Apr 6, 2022 | ERFR | I | TEAS REQUEST FOR RECONSIDERATION RECEIVED | Loading... |
| Apr 6, 2022 | EXPI | T | EX PARTE APPEAL-INSTITUTED | Loading... |
| Apr 6, 2022 | JURT | T | JURISDICTION RESTORED TO EXAMINING ATTORNEY | Loading... |
| Apr 6, 2022 | EXAF | T | EXPARTE APPEAL RECEIVED AT TTAB | Loading... |
| Oct 6, 2021 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED | Loading... |
| Oct 6, 2021 | GNFR | O | FINAL REFUSAL E-MAILED | Loading... |
| Oct 6, 2021 | CNFR | R | FINAL REFUSAL WRITTEN | Loading... |
| Aug 3, 2021 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Aug 3, 2021 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Aug 3, 2021 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Feb 3, 2021 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Feb 3, 2021 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Feb 3, 2021 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Feb 2, 2021 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Oct 28, 2020 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Sep 22, 2020 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for use in the prevention and treatment of cancer and tumors; pharmaceutical preparations for use in the prevention and treatment of infectious, oncological, inflammatory, immune, auto-immune, genetic, and rare diseases, disorders, and conditions; pharmaceutical preparations for human use, namely, pharmaceutical antibodies; pharmaceutical preparations for human use, namely, immunotherapies for the treatment of infectious, oncological, inflammatory, immune, auto-immune, genetic, and rare diseases, disorders, and conditions; pharmaceutical preparations, biological preparations, and gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of infectious, oncological, inflammatory, immune, auto-immune, genetic, and rare diseases, disorders, and conditions; pharmaceutical preparations and substances for conditioning patients to receive therapies for the treatment of infectious, oncological, inflammatory, immune, auto-immune, genetic, and rare diseases, disorders, and conditions; diagnostic preparations for medical purposes; diagnostic biomarker reagents for medical purposes; diagnostic agents, preparations, and substances for medical purposes; reagents for medical use; diagnostic kits comprised of medical diagnostic reagents and assays to test tissue for use in the detection of infectious, oncological, inflammatory, immune, auto-immune, genetic, and rare diseases, disorders, and conditions; diagnostic kits comprised of medical diagnostic reagents and assays to test bodily fluids for use in the detection of infectious, oncological, inflammatory, immune, auto-immune, genetic, and rare diseases, disorders, and conditions; medical diagnostic assays for testing body fluids; medical diagnostic assays for testing body tissue; diagnostic kits comprised of medical diagnostic assays to test for cell expressions for use in identifying pharmaceutical preparations and therapies for treating medical diseases, disorders, and conditions in humans
Class 042
Pharmaceutical drug development services; providing medical and scientific research information in the field of pharmaceuticals; Providing medical and scientific research information in the fields of clinical trials; scientific study and research in the field of pharmaceuticals for the treatment of cancer
Class 044
Providing medical information; providing information in the fields of healthcare, therapeutic properties of pharmaceuticals, health, and wellness
Classification
International Classes
005
042
044